Senior/Executive Medical Director, Clinical Development (New Indications)

Alumis is advancing a proprietary portfolio of TYK2 inhibitors designed to deliver best-in-class efficacy and safety across multiple autoimmune conditions. Our lead compound, envudeucitinib (ESK-001), has demonstrated compelling clinical results in psoriasis and is advancing through pivotal studies in systemic lupus erythematosus (SLE). We are expanding our pipeline with A-005 and exploring additional indications to maximize the therapeutic potential of our portfolio.

---

Position Summary

Alumis is seeking an experienced Executive Medical Director or Senior Medical Director to lead clinical development strategy and execution for Phase 1 and Phase 2 studies in neurology and additional new indications. A centerpiece of this role is A-005, Alumis’s CNS-penetrant TYK2 inhibitor with potential in neuroinflammatory and neurodegenerative diseases — a first-mover opportunity to bring a differentiated mechanism to patients with devastating neurological conditions. This high-impact role will shape Alumis’s expanding clinical portfolio from the ground up, from indication selection and study design through proof-of-concept readout, and will serve as a key scientific leader and external face of the program with investigators, regulatory authorities, and the broader medical community.

---

Key Responsibilities

Clinical Development Strategy & Leadership

· Lead the design, planning, and execution of Phase 1 and Phase 2 clinical studies for A-005 in neurology (e.g., neurodegenerative diseases, movement disorders) and for additional pipeline molecules in inflammatory and immunologic indications

· Develop and refine clinical development plans, including study synopses, protocols, and integrated development strategies for new indications

· Provide clinical and scientific leadership to cross-functional study teams, ensuring alignment on program goals, timelines, and deliverables

· Collaborate with Translational Medicine and Research teams to evaluate and prioritize new indication opportunities based on scientific rationale, competitive landscape, and unmet medical need

Study Execution & Oversight

· Serve as the Medical Monitor for assigned Phase 1 and 2 studies, ensuring patient safety and scientific integrity

· Oversee medical aspects of study conduct, including safety surveillance, protocol amendments, and data review

· Partner with Clinical Operations, Biostatistics, and Regulatory Affairs to ensure efficient study execution and high-quality data generation

· Lead interactions with Data Safety Monitoring Boards (DSMBs) and provide medical input for safety analyses

Regulatory & External Engagement

· Contribute to regulatory strategy and serve as a clinical representative in interactions with FDA and international regulatory authorities (EMA, PMDA, etc.)

· Prepare and review clinical sections of regulatory submissions, including IND amendments, briefing documents, and meeting packages

· Represent Alumis at scientific conferences, advisory boards, and with Key Opinion Leaders (KOLs) to advance clinical programs and gather external insights

· Build and maintain relationships with investigators, academic collaborators, and the broader medical community

Cross-Functional Collaboration

· Work closely with Translational Sciences, Biomarker, and Pharmacology teams to integrate biomarker strategies into clinical study designs

· Collaborate with Commercial and Medical Affairs teams on disease landscape assessments and indication prioritization

· Provide clinical expertise to support business development activities, including evaluation of potential partnerships or in-licensing opportunities

Team Development

· Mentor and develop junior medical staff, fostering a culture of scientific excellence and collaboration

· Contribute to building Alumis's clinical development capabilities as the organization grows

---

Required Qualifications

· MD required; neurology experience required; board certification or fellowship training in Neurology highly desired; additional experience in inflammatory disease areas (e.g., rheumatology, dermatology) a plus

· 10+ years of pharmaceutical/biotechnology industry experience in clinical development, with a significant focus on neurology; experience in immunology or autoimmune diseases a plus

· Demonstrated experience leading Phase 1 and Phase 2 clinical studies from design through data readout

· Track record of successful regulatory interactions (FDA, EMA) and experience preparing IND/CTA submissions

· Deep understanding of early clinical development, including dose-finding strategies, biomarker integration, and adaptive trial designs

· Strong scientific acumen with the ability to critically evaluate preclinical and clinical data to inform development strategy

· Experience with JAK/TYK2 inhibitors or related immunomodulatory mechanisms, preferred

· Excellent leadership, communication, and interpersonal skills with the ability to influence cross-functional teams in a matrixed environment

· Strategic mindset with demonstrated ability to balance scientific rigor with business objectives

---

Preferred Qualifications

· Experience with indication expansion or lifecycle management for neurology or immunology assets

· Prior experience at a small or mid-sized biotechnology company; comfort operating in a fast-paced, resource-conscious environment

· Established relationships with KOLs in neurology; relationships in rheumatology, dermatology, or other inflammatory disease areas also valued

· Experience across multiple therapeutic indications, including neurological diseases (e.g., neurodegenerative diseases, movement disorders) and/or inflammatory conditions such as psoriasis, psoriatic arthritis, lupus, or atopic dermatitis

· Familiarity with regulatory pathways for expedited development (Breakthrough Therapy, Fast Track)

---

What We Offer

· Opportunity to shape the clinical development strategy for a best-in-class TYK2 inhibitor portfolio

· High-visibility leadership role with direct interaction with executive leadership and the CMO

· Collaborative, science-driven culture focused on transforming patient outcomes

· Competitive compensation package including base salary, annual bonus, and equity participation

· Comprehensive benefits including health, dental, vision, 401(k), and generous PTO

---

Travel Requirements

Travel required (approximately 20-30%) to support investigator meetings, scientific conferences, regulatory interactions, and site visits.

The salary range for this position is $300,000 USD to $400,000 USD annually. This salary range is an estimate, and the actual salary may vary based on the Company’s compensation practices.

This position is located in South San Francisco, CA and employees are expected to be onsite Tuesday-Thursday. Remote candidates will be considered on a case-by-case basis.

Alumis Inc. is an equal opportunity employer.

Alumis compensation packages include generous stock option grants for all employees as well as an annual bonus program.

Other benefits include:

• Health insurance premiums paid at 90% for employee, 80% for dependents
• Free access to Genentech Bus & Ferry Share program
• $100 monthly cell phone stipend
• Unlimited PTO for Exempt employees
• Free onsite gym and a kitchen stocked with yummy snacks and drinks!

We are a hard-working, collaborative team on a mission to transform patient’s lives-- and we aspire to elevate, challenge and nurture one another along the way.